Skip to main content
SpringerLink
Log in

Vaccinia virus: a suitable vehicle for recombinant vaccines?

  • Brief Report
  • Published:
Archives of Virology Aims and scope Submit manuscript

Summary

The complications of vaccination against small pox are discussed in relation to the contemplated use as vaccines of recombinant vaccinia viruses carrying the genes for “protective” antigens derived from a range of pathogens. Recombinant vaccines are potentially extremely valuable instruments in the fight against infectious diseases, but caution is needed in their deployment. In addition to the dangers associated with the pathogenicity of various strains of vaccinia virus, there may be problems related to the ecology of the poxviruses—especially orthopoxviruses. Before recombinant vaccinia virus vaccines are widely used, ecological research is urgently needed. It should cover not only the ecology of orthopoxviruses, but also possible interactions between engineered vaccinia viruses released into the environment and wild viruses which may be resident in both target and non-target species in a wide selection of habitats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baxby D (1981) Jenner's smallpox vaccine. The riddle of vaccinia virus and its origin. Heinemann, London

    Google Scholar 

  2. Baxby D, Gaskell RM, Gaskell CJ, Bennett M (1986) Ecology of orthopoxviruses and use of recombinant vaccinia vaccines. Lancet ii: 850–851

    Google Scholar 

  3. Bedson HS, Dumbell KR (1964) Hybrids derived from the viruses of alastrim and rabbit pox. J Hyg (Camb) 62: 141–146

    Google Scholar 

  4. Buller RWL, Smith GL, Cremer K, Notkins AL, Moss B (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinasenegative phenotype. Nature 317: 813–815

    Google Scholar 

  5. Buller RWL, Chakrabarty S, Cooper JA, Twardzik DR, Moss B (1988) Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 62: 866–874

    Google Scholar 

  6. Chandra R, Garg SK, Yadav M (1985) Characteristics of virus isolates from cases of pox in buffaloes. Indian J Vet Med 5: 101–106

    Google Scholar 

  7. Collier LH (1955) The development of a stable smallpox vaccine. J Hyg (Camb) 55: 76–101

    Google Scholar 

  8. Conybeare ET (1964) Illness attributed to smallpox vaccination during 1951–1960. Monthly Bull Min Health Public Health Lab Serv 23: 126–133

    Google Scholar 

  9. Conybeare ET (1964) Illnesses attributed to smallpox vaccination 1951–1960. Part II—Illnesses reported as affecting the central nervous system. Monthly Bull Min Health Public Health Lab Serv 23: 150–159

    Google Scholar 

  10. Donnally HH (1939) Revaccination after two to three years in children primarily vaccinated with culture vaccine (Rivers) compared with those primarily vaccinated with calf lymph virus. JAMA 113: 1796–1800

    Google Scholar 

  11. Donnally HH, Nicholson MM, Anderson WS, Grosvenor MH (1940) Smallpox vaccination of newborn infants with culture virus and with calf lymph virus. Am J Dis Child 59: 322–331

    Google Scholar 

  12. Dumbell KR (1985) Aspects of the biology of orthopoxviruses relevant to the use of recombinant vaccinias as field vaccines. In: Quinnan GV (ed) Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York, pp 9–13

    Google Scholar 

  13. Dumbell KR, Bedson HS (1964) The use of ceiling temperature and reactivation in the isolation of pox virus hybrids. J Hyg (Camb) 62: 133–140

    Google Scholar 

  14. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication. World Health Organization, Geneva

    Google Scholar 

  15. Flexner C, Hügin A, Moss B (1987) Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330: 259–262

    Google Scholar 

  16. Gershon PD, Kitching RP, Hammond JM, Black DN (1989) Poxvirus genetic recombination during natural virus transmission. J Gen Virol 70: 485–489

    Google Scholar 

  17. Halsey NA, Henderson DA (1987) HIV infection and immunization against other agents. N Engl J Med 316: 683–685

    Google Scholar 

  18. Herrlich A, Mayr A, Mahnel H, Muntz E (1963) Experimental studies on transformation of the variola virus into the vaccinia virus. Arch Ges Virusforsch 12: 579–599

    Google Scholar 

  19. Hurst EW (1953) The post-infection encephaliti. Br Med Bull 9: 234–236

    Google Scholar 

  20. Jenner E (1798) An enquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties in England, particularly Gloucestershire, and known by the name of the cow pox. Sampson Low, London

    Google Scholar 

  21. Jones L, Ristow S, Yilma T, Moss B (1986) Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 319: 543

    Google Scholar 

  22. Kaplan C (1960) Titration of vaccinia virus by intravenous injection of chick embryos. Bull WHO 22: 393–397

    Google Scholar 

  23. Kaplan C, Healing TD, Evans N, Healing L, Prior A (1980) Evidence of infection by viruses in small British field rodents. J Hyg (Camb) 84: 285–294

    Google Scholar 

  24. Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H, Lecocq JP (1984) Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312: 163–166

    Google Scholar 

  25. Koprowski H, Celis E, Curtis P, Dietzschold B, Rupprecht C, Tollis M, Wunner W (1987) Rabies experiment. Nature 326: 636

    Google Scholar 

  26. Ladnyi ID, Ziegler P, Kima A (1972) Human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull WHO 46: 593–597

    Google Scholar 

  27. Lane JM, Ruben FL, Neff JM, Millar JD (1969) Complications of smallpox vaccination, 1968. National surveillance in the United States. N Engl J Med 281: 1201–1208

    Google Scholar 

  28. Lourie B, Bingham PC, Evans HH, Foster SO, Nakano JH, Herrmann KL (1972) Human infection with monkeypox virus: laboratory investigation of six cases in West Africa. Bull WHO 46: 633–639

    Google Scholar 

  29. Lourie B, Nakano JH, Kemp GE, Setzer HW (1975) Isolation of poxvirus from an African rodent. J Infect Dis 132: 677–681

    Google Scholar 

  30. Moss B, Smith GL, Gerin JL, Purcell RH (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311: 67–69

    Google Scholar 

  31. Palca J (1986) Genetic manipulation. Living outside regulation. Nature 324: 20

    Google Scholar 

  32. Palca J (1986) Rabies vaccine. Enquiry into Argentine trials. Nature 324: 609

    Google Scholar 

  33. Palca J (1988) Row over vaccine trial. Nature 331: 470

    Google Scholar 

  34. Panicali D, Davis SW, Weinberg RL, Paoletti E (1983) Construction of live vaccines using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus haemagglutinin. Proc Natl Acad Sci USA 80: 5364–5368

    Google Scholar 

  35. Polak MF (1973) Complications of smallpox vaccination in the Netherlands, 1959–1970. In: Regamey RH, Cohen H (eds) International symposium on smallpox vaccine, Bilthoven, 1972. Karger, Basel, pp 235–254 (Symposia series in immunobiological standardization, vol 19)

    Google Scholar 

  36. Polak MF, Beunders BJW, van der Werf A, Sanders EW, van Klaveren JN, Brans LM (1963) A comparative study of clinical reactions observed after application of several smallpox vaccines in primary vaccination of young adults. Bull WHO 29: 311–322

    Google Scholar 

  37. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS (1987) Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316: 673–676

    Google Scholar 

  38. Rivers TM (1931) Cultivation of vaccinia virus for Jennerian prophylaxis in man. J Exp Med 54: 453–461

    Google Scholar 

  39. Rivers TM, Ward SM (1933) Further observations on the cultivation of vaccine virus for Jennerian prophylaxis in man. J Exp Med 58: 635–648

    Google Scholar 

  40. Rivers TM, Ward SM, Baird RD (1939) Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus. J Exp Med 69: 857–866

    Google Scholar 

  41. Smith GL, Mackett M, Moss B (1983) Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302: 490–495

    Google Scholar 

  42. Smith GL, Murphy BR, Moss B (1983) Construction and characterization of an infectious vaccinia virus that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 80: 7155–7159

    Google Scholar 

  43. Strayer DS, Skaletsky E, Cabirac GF, Sharp PA, Corbeil LB, Leibowitz JL (1983) Malignant rabbit fibroma causes immunosuppression in rabbits. J Immunol 130: 399–404

    Google Scholar 

  44. Strayer DS, Sell S (1983) Immunohistology of malignant rabbit fibroma virus—a comparative study with rabbit myxoma virus. J Natl Cancer Inst 71: 105–116

    Google Scholar 

  45. Turnbull HM, McIntosh J (1926) Encephalomyelitis following vaccination. Br J Exp Pathol 7: 181–222

    Google Scholar 

  46. Upton C, McFadden G (1986) Tumorigenic poxviruses: analysis of viral DNA sequences implicated in the tumorigenicity of Shope fibroma virus and malignant rabbit virus. Virology 152: 308–321

    Google Scholar 

  47. Vries E de (1960) Postvaccinial perivenous encephalitis. Elsevier, Amsterdam

    Google Scholar 

  48. Waddington E, Bray PT, Evans AD, Richards IDG (1964) Cutaneous complications of mass vaccination in South Wales 1962. Trans St John's Hosp Dermatol Soc 50: 22–42

    Google Scholar 

  49. Weber G, Lange J (1961) Zur Variationsbreite der “Inkubationszeiten” postvakzinaler zerebraler Erkrankungen. Dtsch Med Wochenschr 86: 1461–1468

    Google Scholar 

  50. Williams RT, Dunsmore JD, Parer I (1972) Evidence for the existence of latent myxoma virus in rabbits [Oryctolagus cuniculi (L.)]. Nature 238: 99–101

    Google Scholar 

  51. Wilson G (1967) The hazards of immunization. The Athlone Press, London

    Google Scholar 

  52. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, Gallo RC (1986) Long-term culture of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 231: 850–853

    Google Scholar 

  53. Zagury D, Leonard R, Fouchard M, Reveil B, Bernard J, Itelle D, Catlan A, Zirimwabagangabo L, Kalumba M, Justin W, Salaun J, Goussard B (1987) Immunization against AIDS in humans. Nature 326: 249–250

    Google Scholar 

  54. Zagury D, Bernard J, Cheynier R, Leonard R, Fouchard M, Reveil B, Itelle D, Zirimwabagangabo L, Mbayo K, Justin W, Salaun J, Goussard B, Dechazal L, Burny A, Nara P, Gallo RC (1988) A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 332: 728–731

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, University of Reading, RG1 5AQ, Reading, England

    C. Kaplan

Authors
  1. C. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplan, C. Vaccinia virus: a suitable vehicle for recombinant vaccines?. Archives of Virology 106, 127–139 (1989). https://doi.org/10.1007/BF01311044

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01311044

Keywords

Search

Navigation